

Clinical Trials Registry at EDA

SN	Submission Date	Study Code (Specified as per the submitted protocol)	Study Title	Sponsor/ CRO	Study Phase (I, II, III, or IV)	EDA Regulatory Decision / Date	Status/Date: - Pending activation - Recruiting - Active - Completed - Withdrawn - Suspended - Terminated	Sites Activation Date “At which the clinical trials will be conducted in Egypt”	Conditions / Therapeutic Area	Interventions Used IMPs & its type (Biological, Pharmaceutical, Innovative, Herbal, or medical device)	Published CT-APSAR/ CT-AmPSAR URL
1.	27/12/2018	M15-991	A multi-center, randomized, double-blind, placebo-controlled induction study to assess the efficacy	Sponsor: Abbvie	III	Approval 26/03/2019	Completed 03/11/2021	1- CRC, Faculty of Medicine, Alexandria University/NA 2-Internal Medicine Department, Faculty of	moderately to severely active Crohn's disease who failed prior biologic treatment	Risankizumab (Biological)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			and safety of Risankizumab in subjects with moderately to severely active Crohn's disease who failed prior biologic treatment					Medicine, Cairo University/NA 3- MASRI CRC, Faculty of Medicine Ain Shams University/NA 4- National Hepatology and Tropical Medicine Institute (NHTMRI)/NA 5-Internal Medicine Department, Faculty of Medicine, Zagazig University/NA			
2.	27/12/2018	M16-000	A Multicenter, Randomized,	Sponsor: Abbvie	III	Approval 26/03/2019	Active 25/02/2021	1- Two sites at the Faculty of Medicine, CRC,	Crohn's disease	Risankizumab (Biological)	NA

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease who respond to induction treatment in M16-006 or M15-991, or					Alexandria University (17/11/20219) 2-National Hepatology and Tropical medicine Research institute (NHTMRI)/NA 3-Faculty of Medicine, Cairo University (22/10/2019) 4-MASRI CRC, Faculty of Medicine Ain Shams University (01/10/2019) 5- Faculty of Medicine, Zagazig University /NA			
--	--	--	---	--	--	--	--	---	--	--	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			completed M15-989								
3.	28/02/2019	M16-066	A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis	Sponsor: Abbvie	III	Approval 10/06/2019	Active 15/05/2023	1- CRC, Faculty of Medicine, Alexandria University (10/10/2019) 2- Air Force Specialized Hospital Research (02/10/2019) 3- National Liver Institute, Menoufia University (03/10/2019)	Ulcerative Colitis	Risankizumab (Biological)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



4.	28/02/2019	M16-067	Multicenter randomized double-blind placebo-controlled induction study to evaluate the efficacy and safety of Risankizumab in subjects with moderately to severely active ulcerative colitis.	Sponsor: Abbvie	III	Approval 10/06/2019	Completed 30/11/2023	1- CRC, faculty of medicine, Alexandria University (02/2022) 2- National Liver Institute, Menoufia University (02/2022) 3- Air Force Specialized Hospital (02/2022)	Active ulcerative colitis.	Risankizumab (Biological)	NA
5.	18/09/2019	ARTEMI S-DM	A multicenter, multinational, prospective,	Sponsor: SANOFI	IV	Approval 09/02/2020	Withdrawn	1- Internal Medicine Department, CRC,	Type 2 diabetes mellitus	Insulin glargine "Toujeo" (Biological)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



		"LPS1539 6"	interventional, single-arm, Phase IV study evaluating the clinical efficacy and safety of 26 weeks of treatment with insulin glargine 300 U/mL (Gla-300) in patients with Type 2 diabetes mellitus uncontrolled on basal insulin					Faculty of Medicine, Alexandria university/NA 2- Internal Medicine Department, Faculty of Medicine, Alexandria University/NA 3- GOTH/NA 4- Faculty of Medicine, Menoufia University/NA 5- Internal Medicine Department, Faculty of			
--	--	-------------	--	--	--	--	--	--	--	--	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



								Medicine, Ain Shams University /NA			
6.	18/11/2019	STAND	A phase II, multicenter, randomized, open label, two arm study comparing the effect of crizanlizumab + SOC alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to	Sponsor: Novartis	II	Approval 05/05/2020	Withdrawn 03/08/2021	1- Abu El Resh Children Hospital/NA	Sickle cell anemia	Crizanlizumab (Biological)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			sickle cell nephropathy								
7.	24/03/2020	STEAD FAST	A Phase III, multicenter, double-blind study to assess efficacy and safety of two doses of crizanlizumab vs placebo with or without hydroxyurea / hydroxycarba mide therapy, in adolescent and adult sickle cell disease patients with	Sponsor: Novartis	III	Approval 05/05/2020	Withdrawn 03/08/2021	1- Faculty of Medicine, Alexandria University/NA 2- Faculty of Medicine, Ain Shams University /NA	Sickle cell anemia	Crizanlizumab (Biological)	NA

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة

البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg

التليفون: 0237484988

موقع الهيئة: www.edaegypt.gov.eg



			vaso-occlusive crisis								
8.	30/03/2020	WA40404	A Phase III b Multicenter, Randomized, double-blind, Placebo-controlled study to evaluate the efficacy and safety of Ocrelizumab in adults with primary progressive Multiple Sclerosis	Sponsor: Roche	IIIb	Approval 23/08/2020	Withdrawn 25/08/2021	1-Sayed Galal Hospital/NA 2-Faculty of Medicine, Alexandria University/NA 3-MASRI CRC, Faculty of Medicine Ain Shams University/NA	Primary progressive multiple sclerosis	Ocrelizumab (Biological)	NA
9.	14/09/2020	1368-0025	Open label long term extension	Sponsor:	IIb	Approval 18/05/2021	Withdrawn 31/10/2021	1- Dermatology department, Faculty of	Generalized pustular psoriasis	Spesolimab (Biological)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			study to assess the safety and efficacy of BI655130 treatment in patients with generalized pustular psoriasis	Boehringer Ingelheim				Medicine, Alexandria University Hospital/NA			
10.	22/09/2020	CNBG20 20003SQ	Multicenter, Randomized, Double blind, parallel placebo controlled, Phase III clinical trial to evaluate the protective efficacy, safety	Sponsor: China National Biotec Group company limited Wuhan institute of	III	Approval 28/03/2022	Completed 31/07/2022	Activation date: 09/2020 1- Vacsera Health Care Facility 2- Kameya Medical Center	COVID-19 Prophylaxis	Inactivated SARS-COV-1 Vaccine (Biological)	Click Here

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			and immunogenicity of Inactivated SARS-COV-2 Vaccines in healthy population aged 18 years old and above	biological products Co. Ltd Beijin institute of biological products Co.Ltd							
11.	13/04/2021	D910DC0001 (Emerald-2)	A phase 3 randomized double blind placebo controlled multicenter study of durvalumab monotherapy	Sponsor: AstraZeneca CRO: IQVIA	III	Approval 12/12/2021	Completed 27/07/2026	1- CRC, Faculty of Medicine, Alexandria University (30/12/2021) 2- National Liver Institute, Menoufia	Hepatocellular carcinoma patients at high risk of recurrence after curative hepatic resection or ablation	Durvalumab\ Bevacizumab (Biological)	Click Here

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة

البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg

التليفون: 0237484988

موقع الهيئة: www.edaegypt.gov.eg

			or in combination with bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma who are at high risk of recurrence after curative hepatic resection or ablation					University (08/11/2021) 3- National Hepatology & Tropical Medicine Research Institute (08/11/2021) 4- Air Force Specialized Hospital (08/11/2021) 5- Clinical Oncology Department, Faculty of Medicine, Assiut University (11/11/2021) 6-Oncology Department,			
--	--	--	--	--	--	--	--	---	--	--	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



								Faculty of Medicine, Mansoura University (13/12/2021) 7-MASRI CRC, Faculty of Medicine, Ain Shams University (17/11/2021) 8-National Cancer Institute (08/11/2021)			
12.	19/05/2021	01- Sputnik- Light- 2021	A phase III, randomized, double-blind, placebo- controlled international multi-site clinical	Sponsor: Human vaccine LLC (Global), Russian ministry	III	Approval 24/08/2021	Completed 31/08/2022	Activation date: Dec 2022 1- National hepatology and tropical medicine center	COVID-19 Prophylaxis	Sputnik Light vector vaccine (Biological)	Click Here

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			trial in parallel assignment to evaluate efficacy immunogenicity and safety of the Sputnik Light vector vaccine in adults in the SARS-Cov-2 infection prophylactic treatment	of healthcare – Gamalya (Local) CRO: PDC				2- Katameya Medical Center			
13.	25/05/2021	KATE-3	A randomized, multi-center, double blind, placebo-controlled phase III study of the efficacy and safety of	Sponsor: Roche	III	Approval 05/12/2021	Withdrawn 19/12/2022	1- NEMROCK, Faculty of Medicine, Kasr Al-Ainy Hospital, Cairo University /NA	HER2-positive and PD-L1-positive locally advanced or metastatic breast cancer	Trastuzumab Emtansine/ Atezolizumab (Biological)	NA

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة

البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg

التليفون: 0237484988

موقع الهيئة: www.edaegypt.gov.eg

			Trastuzumab Emtansine in combination with Atezolizumab or placebo in Pts with HER2-positive and PD-L1- positive locally advanced or metastatic breast cancer who have received prior Trastuzumab + Atezolizumab and Taxane- based therapy					2- Shefaa Al- Orman Hospital/NA 3- Baheya Hospital /NA			
--	--	--	---	--	--	--	--	--	--	--	--

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



14.	18/08/2021	MO42541	A phase III, open label, randomized study of Atezolizumab with Lenvatinib or Sorafenib versus Lenvatinib or sorafenib alone in hepatocellular carcinoma previously treated with Atezolizumab and Bevacizumab	Sponsor: Roche CRO: IQVIA for Monitoring	III	Approval 02/02/2022	Active 19/04/2024	1- Air Force Specialized Hospital (17/01/2024)	Hepatocellular carcinoma	Atezolizumab/ Lenvatinib/ Sorafenib (Biological)	Click Here
-----	------------	---------	--	---	-----	------------------------	----------------------	---	--------------------------	---	----------------------------

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة

البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg

التليفون: 0237484988

موقع الهيئة: www.edaegypt.gov.eg

15.	02/09/2021	COVID_VACC_1	A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Inactivated SARS-CoV-2 Vaccine Against COVID-19 in Healthy Adults	Sponsor: National research center CRO: Clinmax	I	Approval 09/11/2021	Suspended 09/12/2021	1- National Research Center (11/11/2021)	Covid-19 Prophylaxis	Inactivated SARS-CoV-2 Vaccine (Biological)	Click Here
16.	17/01/2022	SPHINX-EGYPT SPHINX2 2122020	Safety and Immunogenicity Study of EgyVax Vaccine Candidate for	Sponsor: - EVA PHARM A - VSVRI	I	Approval 03/02/2022	Completed 30/04/2023	Al-Manial Specialized University Hospital, Cairo University	Covid-19 Prophylaxis	EgyVax Vaccine (Biological)	Click Here

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Prophylaxis of SARS-CoV-2 Infection (COVID-19)	- supreme council of university hospitals - Ministry of higher education and scientific research CRO: Dataclin				Hospitals (06/02/2022)			
17.	04/11/2021	GBT2104-131	A randomized double blinded placebo controlled multicentre study to access the safety and	Sponsor: Global blood therapeutics Inc. \ Pfizer	III	Approval 14/06/2022	Completed 30/05/2025	1-Pediatric Department, Faculty of Medicine, Mansoura University/NA	sickle cell disease patients with Vaso-occlusive crisis	Inclacumab (Biological)	Click Here

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			efficacy of Inclacumab in participants with sickle cell disease experiencing Vaso- occlusive crisis	CRO: MCT					2-Pediatric Department, Faculty of Medicine, Zagazig University (28/02/2023) 3- MASRI-CRC, Faculty of Medicine, Ain Shams University (04/03/2023) 4-Pediatric Hematology Department & CRC, Faculty of Medicine, Alexandria University/NA 5- Abo El-Resh Hospital & CRC,			
--	--	--	--	-------------	--	--	--	--	--	--	--	--

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



								Faculty of Medicine, Cairo University and Hematology Department, (28/02/2023)			
18.	04/01/2022	GBT2104-132	A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent	Sponsor: Global blood therapeutics Inc.\ Pfizer CRO: MCT	III	Approval 14/06/2022	Withdrawn 29/06/2023	1-Pediatric Department, Faculty of Medicine, Mansoura University/NA 2-Pediatric Department, Faculty of Medicine, Zagazig University/NA 3- MASRI, CRC, Faculty of Medicine Ain	Sickle cell disease patients with Vaso-occlusive crisis	Inclacumab (Biological)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Vaso-occlusive Crises (GBT-132)					Shams University/NA 4-Pediatric Hematology Department, CRC, Faculty of Medicine, Alexandria University/NA 5- CRC, Faculty of Medicine, Cairo University and Hematology Department, Abo El-Resh Hospital/NA			
19.	28/11/2021	GBT2104-133	An Open-label Extension Study to Evaluate the	Sponsor: Global blood therapeuti	III	Approval 14/06/2022	Withdrawn 17/12/2023	1-Pediatric Department, Faculty of Medicine,	sickle cell disease	Inclacumab (Biological)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Long-term Safety of Inclacumab Administered to Participants with Sick Cell Disease Who Have Participated in an Inclacumab Clinical Trial	cs Inc.\ Pfizer CRO: MCT				Mansoura University/NA 2- Pediatric Department, Faculty of Medicine, Zagazig University/NA 3- MASRI, CRC, Faculty of Medicine Ain Shams University/NA 4-Pediatric Hematology Department& CRC, Faculty of Medicine, Alexandria/NA University Hospital			
--	--	--	--	---------------------------------	--	--	--	--	--	--	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



								5- Abo El-Resh Hospital & CRC, Faculty of Medicine, Cairo University and Hematology Department/NA			
20.	08\06\2022	Consonance-MN39159	An open-label, single-arm 4-year study to evaluate effectiveness and safety of ocrelizumab treatment in patients with progressive multiple sclerosis	Sponsor: F. HOFFMAN-ROCHE LTD CRO: IQVIA (for monitoring activities only)	III	Approval 20/09/2022	Completed 08/02/2026	1- CRC, Faculty of Medicine, Alexandria University (05/03/2019) 2- MASRI-CRC, Faculty of Medicine, Ain Shams University (25/02/2021)	Progressive multiple sclerosis	Ocrelizumab (Biological)	Click Here

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



21.	14/08/2022	CAIN457 A2310	A randomized, double-blind, placebo- and active controlled multicenter trial to demonstrate efficacy of subcutaneous Secukinumab compared to placebo and etanercept (in a single blinded arm) after twelve weeks of treatment, and to assess the safety,	Sponsor: Novartis CRO: MCT	III	Approval 04/12/2022	Terminated (by the Sponsor) 31/03/2023	1- CRC, Faculty of Medicine, Alexandria University Hospital (11/01/2017) 2- Dermatology Department, Faculty of Medicine, Ain Shams University Hospital (22/01/2017)	Treatments of severe chronic plaque psoriasis	Secukinumab (Biological)	Click Here
-----	------------	------------------	--	---	-----	------------------------	---	--	---	---------------------------------	----------------------------

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			tolerability, and long-term efficacy in subjects from 6 to less than 18 years of age with severe chronic plaque psoriasis								
22.	19/12/2022	Recbio	A multi-center randomized double blind placebo-controlled phase 2/3 trial to evaluate the efficacy, safety and immunogenicity of the	Sponsor: Jiangsu Recbio Technology Co., Ltd CRO: PDC	II/III	Refusal 20/04/2022	NA	1.Egyptian CDC 2.Katameya Medical Center 3.National Hepatology and Tropical Medicine Research Institute (NHTMRI)	Prophylactic Vaccine for COVID-19	Recombinant two component COVID-19 vaccine (Biological)	NA

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة

البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg

التليفون: 0237484988

موقع الهيئة: www.edaegypt.gov.eg

			recombinant two component COVID-19 vaccine (CHO) cell in adult aged 18 years and older								
23.	06/06/2023	FUZION CNTO19 59CRD	A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants	Sponsor: Janssen Research and Development CRO: MCT	III	Approval 13/08/2023	Recruiting 09/12/2024	1- National Hepatology and Tropical Medicine Research Institute (NHTMRI)/ (09/12/2024) 2- CRC, Faculty of Medicine, Alexandria University	Fistulizing perianal Crohn's disease	Guselkumab (Biological)	Click Here

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			with Fistulizing, Perianal Crohn's Disease "FUZION CD"					(09/12/2024) 3- Department of Internal Medicine, Kasr Al Aini Hospital, Cairo University (09/12/2024) 4- MASRI CRC, Faculty of Medicine, Ain Shams University (09/12/2024)			
24.	14/05/2023	MP- ADA1-01	A Phase I, randomized, double-blind, 2-arm, parallel group trial to compare pharmacokinetics of Adessia	Sponsor: Minapharm CRO: CRS Clinical Research	I	Approval 10/08/2023	Completed 17/11/2023	1- CRS clinical research services, Berlin GmbH/NA 2- CRS clinical research services, Mannheim GmbH/NA	Inflammatory disease (Biosimilar to Humira)	Adessia (Biological)	Click Here

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة

البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg

التليفون: 0237484988

موقع الهيئة: www.edaegypt.gov.eg

			with EU-authorized Humira in healthy male and female participants”	Services Berlin GmbH							
25.	04/05/2023	MOM-M281-006	Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study with a	Sponsor: Janssen Research and Development CRO: MCT	II/III	Approval 19/07/2023	Terminated (by the sponsor) 21/02/2025	1- National Cancer Institute, Cairo University (13/03/2024) 2- Oncology center, Mansoura University Hospital (13/03/2024) 3- Department of Internal Medicine, Kasr Al Eini Hospital, Cairo University (13/03/2024)	Warm Autoimmune Hemolytic Anemia	M281 (Biological)	Click Here

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Long-term Open-label Extension”					4- Naser Institute Hospital for Research and Treatment (13/03/2024) 5- CRC, Faculty of Medicine, Alexandria University (13/03/2024) 6- MASRI CRC, Faculty of Medicine, Ain Shams University (13/03/2024)			
26.	09\10/2023 shift to amendment submission	EMERAL D-3) D910VC0 0001	A Phase III, Randomized, Open-Label, Sponsor- Blinded,	Sponsor: AstraZeneca CRO: IQVIA	III	Approval 08/02/2024	Active: 22/08/2024	1- Oncology Department &CRC, Faculty of Medicine, Alex University/NA	Locoregional Hepatocellular Carcinoma	Durvalumab / Tremelimumab/ nvatinib /TACE	Click Here

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



	26\12\2023		Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma					2- National Hepatology and Tropical Medicine Research Institute (NHTMRI) (09/06/2024) 3- Egyptian Liver Hospital (13/06/2024) 4-National Liver Institute, Menoufia (25/01/2024)		(Biological)	
--	------------	--	--	--	--	--	--	---	--	--------------	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			(EMERALD-3)								
27.	14/12/2023	BCD-178	A Double-Blind Randomized Clinical Study of the Efficacy and Safety of BCD 178 and Perjeta as Neoadjuvant Therapy in HER2-Positive Breast Cancer	Sponsor: JSC BIOCAD CRO: Dataclin	III	Approval 22/04/2024	Withdrawn 25\12\2024	1-Clinical Oncology Department, Faculty of Medicine, Alexandria University Hospital/NA 2- Clinical Oncology Department, Faculty of Medicine, Cairo University Hospital/NA	Her-2 positive breast cancer	BCD-178 (Biological)	NA
28.	08/01/2024	SerpinPc 102	A Global, Open-label, Adaptive	Sponsor: Apcintex	IIb	Conditional Approval 13/06/2024	Withdrawn 16/01/2025	1- MASRI CRC, Faculty of Medicine, Ain	Hemophilia A or Moderately Severe to	SerpinPC 102 (Biological)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects with Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (AP-0102)	CRO: MCT		Final Approval 31/10/2024		Shams University/NA	Severe Hemophilia B		
29.	08/01/2024	SerpinPC 103	A Global, Open-label Study to Investigate the Efficacy and Safety of SerpinPC in	Sponsor: Apcintex CRO: MCT	Iib	Conditional Approval 13/06/2024 Final Approval 31/10/2024	Withdrawn 16/01/2025	1- MASRI CRC, Faculty of Medicine Ain Shams University/NA	Hemophilia B with Inhibitors	Serpin PC 103 (Biological)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Subjects with Hemophilia B with Inhibitors (AP-0103)								
30.	08/02/2024	D9185C00001'' TILIA'	A Phase III, Multicenter, Randomized, Double-bind, Parallel-group, Placebo-Controlled study to evaluate the efficacy and safety of Tozorakimab (MEDI3506) in patients hospitalized for viral lung	Sponsor: AstraZenca CRO: IQVIA	III	Conditional Approval 04/08/2024	Withdrawn 30/01/2025	1- Chest Disease Department, Air Force Specialized Hospital/NA 2- MASRI CRC, Faculty of Medicine Ain Shams University/NA 3- Chest Department, CRC, Faculty of Medicine, Alexandria University/NA	Patients hospitalized for viral lung infection	Tozorakimab (Biological)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			infection requiring supplemental oxygen								
31.	16/01/2025	GA45329-Ametrine 1	A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 In Patients with Moderately to Severely Active	Sponsor: Roche	III	Approval 10/03/2025	Withdrawn 10/09/2025	1- Internal Medicine, Department& CRC, Faculty of Medicine, Alexandria University/NA	Patients with Moderately to Severely Active Ulcerative Colitis	RO7790121 (Biological)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Ulcerative Colitis								
32.	16/01/2025	GA45330-Ametrine 2	A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy with RO7790121 In Patients with Moderately to Severely Active Ulcerative Colitis	Sponsor: Roche	III	Approval 10/03/2025	Withdrawn 10/09/2025	1- Internal Medicine Department& CRC, Faculty of Medicine, Alexandria University/NA	Patients with Moderately to Severely Active Ulcerative Colitis	RO7790121 (Biological)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



33.	11\05\2025	GA45331 SEBRITE-1	A Phase III Multicenter Double Blind Placebo Controlled Treat through study to assess the efficacy and safety of Induction and Maintenance therapy with RO7790121 in patients with moderately to severely active Crohn's disease	Sponsor: Roche	III	Approval 01/06/2025	Withdrawn 23/06/2026	1- Gastroenterology Department & CRC, Faculty of Medicine, Alexandria University/NA 2- Gastroenterology, Air Force Specialized Hospital/NA 3- Hepatology Department, National Liver Institute, Menoufia University/NA	Crohn's Disease	RO7790121 (Biological)	Click Here
34.	20/05/2025	M20-465	A Phase III Multicenter, Randomized,	Sponsor: Abbvie	III	Approval 08/10/2025	Withdrawn 17/03/2026	1- Dermatology Department, Air Force	Moderate to Severe	Lutikizumab (Biological)	Click Here

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Double-Blind Placebo- Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa					Specialized Hospital/NA 2- Dermatology, Andrology and Venerology Department& CRC, Faculty of Medicine, Alexandria University/NA 3- MASRI CRC, Faculty of Medicine, Ain Shams University/NA	Hidradenitis Suppurativa		
35.	18/09/2025	GA45332 SEBRITE- 2	A Phase III, Multicenter, Double-Blind, Placebo-	Sponsor: Roche	III	Approval 20/10/2025	Withdrawn 23/06/2026	1- Gastroenterolo gy Department & CRC, Faculty of Medicine,	Crohn's Disease	RO7790121 (Biological)	Click Here

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Controlled Study to assess the efficacy and safety of induction therapy with RO7790121 in patients with moderately to severely active Crohn's disease					Alexandria University/NA 2- Gastroenterology Department, CRC Air Force Specialized Hospital/NA 3- Hepatology Department, National Liver Institute, Menoufia University/NA			
36.	24/10/2025	221530/JA DE	A Randomized, Double-Blind, Placebo Controlled Phase III Study to Evaluate Dostarlimab as	Sponsor: GSK CRO: MCT	III	Approval 04/05/2026	Withdrawn 30/07/2026	1- MASRI CRC, Faculty of Medicine Ain Shams University/NA	Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma	Dostarlimab (Biological)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Sequential Therapy After Chemoradiation In Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma					2- Clinical Oncology Department& CRC, Faculty of Medicine, Alexandria University/NA 3- Clinical Oncology Department, Faculty of Medicine, Mansoura University Hospital/NA 4- Clinical oncology department, Nasser Institute for Research and Treatment/NA			
--	--	--	---	--	--	--	--	---	--	--	--

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



								5- Clinical Oncology Department, Faculty of Medicine, Assiut University Hospital/NA			
37.	17/12/2020	CEGA23 0B2404	A Phase IV Multicenter Open Label Study to Determine the Safety, Tolerability and Clinical Outcomes Following Oral Administration of Egaten (Triclabandazo	Sponsor: Novartis CRO: MCT	IV	Approval 12/04/2021	Completed 11/12/2025	1-Pediatric Hepatology Unit, Abu El Rich Al Mounira Children Hospital, Cairo University (11/01/2023). 2-CRC, Faculty of Medicine, Alexandria University (25/01/2023)	Fascioliasis	Triclabandazole (Egaten) (Pharmaceutical)	NA

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			le) in patients 6 Years of Age or Older with Fascioliasis (Egaten)								
38.	-----	CLEE011 A3201C RIGHT Choice	A Phase II Randomized Study of the Combination of Ribociclib Plus Goserelin Acetate with Hormonal Therapy Versus Physician Choice Chemotherapy in Premenopausal or	Sponsor: Novartis CRO: MCT	II	Approval 08/01/2020	Completed 08/01/2023	1- MASRI CRC, Faculty of Medicine, Ain Shams University, (28/01/2020). 2- Baheya Hospital Research Center (19/01/2020) 3- NEMROC, Kasr Al Aini Hospital, Cairo University (05/03/2020)	HER-2 Negative Breast Cancer	Ribociclib Plus Goserelin / Physician Choice Chemotherapy (Pharmaceutical)	NA

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Perimenopausal Patients with Hormone Receptor-Positive/HER2-Negative Inoperable Locally Advanced or Metastatic Breast Cancer - RIGHT Choice Study (RIGHT Choice)					4- Nasser Institute Cancer Center (26/03/2020)			
39.	06/04/2021	CLJN452 D12201C	A Randomized, Double-Blind, Parallel-Group,	Sponsor: Novartis CRO: MCT	III	Approval 09/11/2021	Withdrawn 20/11/2022	1- National Hepatology and Tropical Medicine Research Institute (NHTMRI)/NA	Treatment of Adult Patients with Non-Alcoholic Steatohepatitis	Tropifexor (LJN452) and Licogliflozin (LIR066)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Multicenter Study to Assess Efficacy, Safety and Tolerability of Oral Tropifexor (LJN452) and Licogliflozin (LIR066) Combination Therapy Compared to Each Monotherapy for Treatment of Adult Patients with Non-Alcoholic					2- Egyptian Liver Research Institute and Hospital (ELRIAH)/NA	(NASH) and Liver Fibrosis	Combination Therapy (Pharmaceutical)	
--	--	--	--	--	--	--	--	---	---------------------------	--------------------------------------	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Steatohepatitis (NASH) and Liver Fibrosis ELIVATE								
40.	06/07/2021	MK4482-002	A Phase 2/3, Randomized Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokinetics of MK-4482 In Non-Hospitalized Adults with COVID-19	Sponsor: MSD	II/III	Approval 08/08/2021	Completed 05/05/2022	1- Abbasya Chest Hospital (21/09/2021) 2- Helwan Fever Hospital (22/09/2021) 3- Imbaba Fever Hospital/NA 4- Abbasya Fever Hospital (20/09/2021) 5- National Hepatology and Tropical Medicine Research Institute	Non-Hospitalized Adults with COVID-19	Molnupiravir (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



								(NHTMRI) (22/09/2021) 6- National Center for Allergies and Chest, Imbaba (22/09/2021)			
41.	03/08/2021	Mol_0607 202	A Multi- Centre, Two- Arm, Parallel Group, Randomized, Double- Blinded, Phase III Trial to Assess Efficacy and Safety of Molpravir in Treatment of Patients with	Sponsor: EVA Pharma	III	Refusal 17/04/2022	NA	1- Alexandria Fever Hospital/NA 2- National Hepatology and Tropical Medicine Research Institute (NHTMRI)/NA 3- Fayoum General Hospital/NA 4- Abbasya Chest Hospital/NA 5- CDC, Imbaba Hospital/NA	Mild to Moderate COVID-19 Infection	Molnupiravir (Pharmaceutical)	NA

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Mild to Moderate COVID-19 Infection								
42.	24/10/2021	M14-430	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's	Sponsor: Abbvie	III	Approval 07/07/2022	Active (30/12/2021)	1- CRC Air Force Specialized Hospital (28/01/2019). 2- National Liver Institute Menoufia University (21/01/2019). 3- CRC, Faculty of Medicine, Alexandria University (05/02/2019). 4- MASRI CRC, Faculty of	Chron's Disease	Upadacitinib/ matching placebo (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Disease Who Completed the Studies M14-431 or M14-433					Medicine, Ain Shams University (25/10/2020). 5- National Hepatology and Tropical Medicine Research Institute (NHTMRI) (29/01/2019).			
43.	-----	BO40336 ALINA	A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib	Sponsor: Roche	III	Approval 29/05/2019	Active (29/10/2021)	1- NEMROCK, Kasr Al Aini Hospital, Cairo University (19/09/2019).	Lung Cancer	Alectinib / Platinum-based Chemotherapy (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Versus Adjuvant Platinum- Based Chemotherapy in Patients with Completely Resected Stage Ib (Tumors $\geq$ 4 Cm) To Stage IIa Anaplastic Lymphoma Kinase- Positive Non- Small-Cell Lung Cancer (ALINA)								
--	--	--	--	--	--	--	--	--	--	--	--

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



44.	12/12/2021	Cl_Tr_17 122019 MIRACL E-ALA	A Multicenter, Interventional, Two-Arm, Parallel-Group, Randomized, Double-Blinded, Placebo- Controlled, Phase IV Trial to Evaluate the Efficacy of Alpha-Lipoic Acid in the Treatment of Patients with Symptomatic Diabetic Polyneuropathy in Egypt	Sponsor: EVA Pharma CRO: MARC	IV	Approval 12/10/2022	Completed 11/12/2024	1- Diabetes, Metabolism, and Lipidology Unit, Department of Internal Medicine, Alexandria University Hospital (27/10/2022). 2- Department of Internal Medicine, Ain Shams University Hospital (01/12/2022). 3- Department of Internal Medicine, Menoufia University	Treatment of Symptomatic Diabetic Polyneuropath y	Alpha-Lipoic Acid (Thiotacid)/ matching placebo (Pharmaceutical)	NA
-----	------------	---------------------------------------	--	---	----	------------------------	-------------------------	---	---	---	----

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة

البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg

التليفون: 0237484988

موقع الهيئة: www.edaegypt.gov.eg

			(MIRACLE-ALA)					Hospital (29/01/2023). 4- Department of Internal Medicine, Intrinsic Specialized Hospital, Mansoura University, (09/01/2023). 5- Department of Internal Medicine, Diabetes and Endocrinology Unit, Beni-Suef University Hospital, (03/04/2023).			
--	--	--	---------------	--	--	--	--	--	--	--	--

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



45.	12/12/2021	MK4482-013 MOVE-Ahead	A Phase 3 Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory Confirmed SARS-COV 2 Infection with Symptoms) in Adults.	Sponsor: MSD	III	Approval 18/01/2022	Completed 16/11/2022	1- MASRI CRC, Faculty of Medicine, Ain Shams University (22/03/2022). 2- CRC Air Force Specialized Hospital (22/03/2022). 3- National Hepatology and Tropical Medicine Research Institute (NHTMRI) (22/03/2022).	Prophylaxis of COVID-19	Molnupiravir/ matching placebo (Pharmaceutical)	NA
-----	------------	--------------------------	--	--------------	-----	------------------------	-------------------------	--	-------------------------	---	----

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			(MOVE-Ahead)					4- Imbaba Fever Hospital (30/05/2022). 5- National Center for Allergies and Chest Imbaba (30/05/2022).			
46.	30/03/2022	GBT440-032	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease	Sponsor: GBT (Subsidiary of Pfizer) CRO: CTI	III	Approval 31/07/2022	IMP Dosing Pause 02/05/2024 Terminated (by the Sponsor) 29/09/2024	1- MASRI CRC, Faculty of Medicine, Ain Shams University, (26/01/2021) 2- CRC, Faculty of Medicine Alexandria University (27/01/2021). 3- Pediatrics Hematology Department, Abu	Sickle Cell Disease	Voxelotor/ matching placebo (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			(HOPE Kids 2)					El Rich Al Mounira Children Hospital, Cairo University (25/01/2021). 4- Pediatrics Hematology Department, Zagazig University Hospital (31/01/2021).			
47.	18/04/2022	GBT440-034	An Open Label Extension Study of GBT440 Administered Orally to Patients with	Sponsor: GBT (Subsidiary of Pfizer) CRO: IQVIA	III	Approval 02/08/2022	Terminated (by the Sponsor) 30/09/2024	1- Pediatrics Hematology Department, Abu El Rich Al Mounira Children Hospital, Cairo University (16/04/2019).	Sickle Cell Disease	Voxelotor (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Sickle Cell Disease who Have Participated in GBT440 Clinical Trials					2- MASRI CRC, Faculty of Medicine, Ain Shams University (15/04/2019). 3- CRC, Faculty of Medicine, Alexandria University, Site I (20/04/2019) Site II (18/04/2019) 4- Pediatrics Hematology Department Zagazig University Hospital (14/04/2019).			
--	--	--	---	--	--	--	--	---	--	--	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



48.	12/06/2022	CLSYN.1 702 (OASIS-9)	A 2x2 Factorial Randomized Controlled Trial of CoLchicine and spironolactone in Patients With myocardial infarction/SY NERGY Stent Registry – Organization to Assess Strategies for Ischemic Syndromes 9 (OASIS-9)	Sponsor: Hamilton Health Science CRO: Clinmax	III/IV	Approval 24/07/2022	Completed 01/08/2024	1- Cardiology Department, Mansoura University Hospital (25/09/2022). 2- Cardiology Department, Suez Canal University Hospital (24/09/2022). 3- Cardiology Department, Fayoum General Hospital, (20/09/2022). 4- Cardiology Department, Tamia Central	STEMI/Non- STEMI Myocardial Infarction	Colchicine, Spironolactone/ matching placebo (Pharmaceutical)	NA
-----	------------	-----------------------------	---	--	--------	------------------------	-------------------------	--	---	--	----

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة

البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg

التليفون: 0237484988

موقع الهيئة: www.edaegypt.gov.eg

								Hospital, (20/09/2022). 5- Cardiology Department, El Kharga Specialized Hospital (28/09/2022). 6- National Heart Institute (26/09/2022).			
49.	15/06/2022	20140106	Phase 1b/2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory	Sponsor: Onyx Pharmace uticals (Subsidiar y of Amgen)	Ib/II	Approval 23/08/2022	Withdrawn 19/06/2023	1- CRC, Children Cancer Hospital Egypt /NA	Relapsed or Refractory Acute Lymphoblastic Leukemia	Carfilzomib (Pharmaceutical)	NA

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Acute Lymphoblastic Leukemia	CRO: IQVIA							
50.	18/07/2022	AG348-C-020	A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects with Sick Cell Disease	Sponsor: Agios CRO: MCT	II/III	Approval 27/09/2022	Withdrawn 21/08/2023	1- CRC, Faculty of Medicine, Alexandria University /NA 2- Pediatric Hematology Department, Zagazig University Hospital, /NA 3- CRC, Faculty of Medicine, Cairo University /NA 4- Pediatrics Hematology Department, Abu	Sickle Cell Disease	Mitapivat / matching placebo (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



								El Rich Al Mounira Children Hospital, Cairo University /NA 5- Pediatric Hematology Department, Mansoura University Hospital /NA 6- MASRI CRC, Faculty of Medicine, Ain Shams University /NA			
51.	26/07/2022	F901318/ 0041	A Phase III, Adjudicator- Blinded, Randomized Study to	Sponsor: F2G CRO: IQVIA	III	Approval 11/10/2022	-----	1- Oncology Center Mansoura University/NA CRC, Faculty of Medicine,	Invasive Fungal Disease caused by Aspergillus species	Olorofim / Ambisome (Pharmaceutical)	NA

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Evaluate the Efficacy and Safety of Treatment with Olorofim Versus Treatment with Ambisome® Followed by Standard of Care (SOC) in Patients with Invasive Fungal Disease (IFD) Caused by Aspergillus Species					Alexandria University /NA 3- Air Force Specialized Hospital CRC /NA 4- MASRI CRC, Faculty of Medicine, Ain Shams University, /NA 5- Oncology Department, Faculty of Medicine, Zagazig University Hospital /NA 6- National Cancer Institute /NA			
--	--	--	---	--	--	--	--	--	--	--	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



								7- CRC, Faculty of Medicine, Cairo University /NA 8- Nasser Institute for Research and Treatment /NA			
52.	27/07/2022	APD334-202	A Multicenter Randomized Double Blinded Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to	Sponsor: Arena Pharmaceuticals (Subsidiary of Pfizer)	III	Approval 23/08/2022	Terminated (by the Sponsor) 20/03/2025	1- CRC, Faculty of Medicine, Alexandria University, (22/06/2021). 2- CRC Air Force Specialized Hospital (21/06/2021). 3- National Liver Institute, Menoufia University (20/06/2021).	Moderately to Severe Active Crohn's Disease	Etrasimod / matching placebo (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Severe Active Crohn's Disease (Etrasimod)					4- National Hepatology and Tropical Medicine Research Institute (NHTMRI) (27/06/2021). 5- Integrated Clinical and Research Center for Intestinal Disorders (ICRID), Cairo University (23/06/2021). 6- Egyptian Liver Research Institute and Hospital (15/06/2021). 7- MASRI CRC, Faculty of			
--	--	--	---	--	--	--	--	--	--	--	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



								Medicine, Ain Shams University (16/06/2021). 8-Theodor Bilharz Research Institute (11/07/2021).			
53.	07/08/2022	EFC1721 5 LEAP-2- MONO	A Phase 3, Multicenter, Multinational Randomized Double-Blind Double-Dummy, Active Comparator Study to Evaluate the Efficacy and Safety of Venglustat in	Sponsor: Sanofi	III	Approval 24/10/2022	Withdrawn 16/03/2025	1- CRC, Faculty of Medicine, Alexandria University /NA	Gaucher Disease Type 3 (GD3)	Venglustat/ Cerezyme (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Adult and Pediatric Patients with Gaucher Disease Type 3 (GD3) who Have Reached Therapeutic Goals with Enzyme Replacement Therapy (LEAP-2-MONO)								
54.	15/08/2022	AG348-C-017	A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter	Sponsor: Agios CRO: MCT	III	Approval 02/11/2022	Withdrawn 26/06/2023	1-Pediatrics Hematology Department, Abu El Rich Al Mounira Children	Non-Transfusion-Dependent Alpha or Beta Thalassemia	Mitapivat / matching placebo (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Study Evaluating the Efficacy and Safety of Mitapivat in Subjects with Non- Transfusion- Dependent Alpha- or Beta- Thalassemia (ENERGIZE)					Hospital, Cairo University /NA 2- CRC, Faculty of Medicine, Cairo University /NA 3- MASRI CRC, Faculty of Medicine, Ain Shams University/NA			
55.	15/08/2022	AG348- C-018	A Phase 3, Double-blind, Randomized, Placebo- Controlled, Multicenter Study	Sponsor: Agios CRO: MCT	III	Approval 02/11/2022	Withdrawn 26/06/2023	1-Pediatrics Hematology Department, Abu El Rich Al Mounira Children Hospital, Cairo University /NA	Transfusion- Dependent Alpha or Beta Thalassemia	Mitapivat / matching placebo (Pharmaceutical)	NA

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Evaluating the Efficacy and Safety of Mitapivat in Subjects with Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)					2- CRC, Faculty of Medicine, Cairo University /NA 3- MASRI CRC, Faculty of Medicine, Ain Shams University, /NA			
56.	29/08/2022	4202-HEM-301	An Adaptive, Randomized, Placebo-Controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase	Sponsor: Forma Therapeutics CRO: MCT	III	Approval 11/12/2022	Active (17/01/2025)	1- CRC, Faculty of Medicine Alexandria University (12/08/2024). 2- Pediatric Hematology Department, Zagazig University	Sickle Cell Disease	Etavopivat / matching placebo (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Activator in Patients with Sickle Cell Disease (Hibiscus Study)					Hospital (31/07/2024) 3- CRC, Faculty of Medicine, Cairo University (07/07/2024). 4- Pediatrics Hematology Department, Abu El Rich Al Mounira, Cairo University (31/07/2021). 5- MASRI CRC, Faculty of Medicine, Ain Shams University (07/07/2024)			
57.	29/09/2022	GO42784 LIDERA	A Phase III, Randomized,	Sponsor: Roche	III	Approval 04/12/2022	Active (09/08/2023)	1- CRC, Faculty of Medicine,	Estrogen Receptor-Posi	Giredestrant / Physician	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician's Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Posi tive, Her2-	CRO: MCT				Alexandria University (24/05/2023). 2- Medical Research Institute, Alexandria University (03/04/2023). 3- Oncology Center, Mansoura University (03/04/2023) 4- NEMROCK, Kasr Al Ainy Hospital, Cairo University (13/04/2023) 5- Oncology Department, El	tive, Her2- Negative Early Breast Cancer	Choice of Adjuvant Endocrine Monotherapy (Pharmaceutical)	
--	--	--	--	-------------	--	--	--	--	--	---	--

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة

البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg

التليفون: 0237484988

موقع الهيئة: www.edaegypt.gov.eg

			Negative Early Breast Cancer (LIDERA)					Demerdash Hospital, Ain Shams University (08/05/2023). 6- Gustave Roussy International Hospital (05/06/2023). 7- Sohag Oncology Center (05/06/2023)			
58.	16/11/2022	(ACTIV-2D/A5407)	A Phase 3, Multicenter, Randomized, Double-Blind, 24-Week Study of the Clinical and Antiviral	Sponsor: Shionogi CRO: IQVIA	III	Approval 31/01/2023	Withdrawn 26/09/2023	1- National Hepatology and Tropical Medicine Research Institute (NHTMRI) /NA 2- MASRI CRC, Faculty of Medicine, Ain	Covid-19 treatment	S-217622 / matching placebo (Pharmaceutical)	NA

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة

البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg

التليفون: 0237484988

موقع الهيئة: www.edaegypt.gov.eg

			Effect of S-217622 Compared with Placebo in Non-Hospitalized Participants with COVID-19 (ACTIVE)					Shams University /NA 3- CRC, Faculty of Medicine, Alexandria University /NA 4- CRC Air Force Specialized Hospital /NA 5- National Institute for Chest Allergy and Diseases /NA 6- Imbaba Fever Hospital /NA			
59.	28/11/2022	RBSC2161	A Phase 2a Randomized, Double-Blind, Placebo-Controlled	Sponsor: Salix pharmaceuticals	Ila	Approval 05/02/2023	Withdrawn 06/11/2023	1-Pediatric Hematology Department, Abu El Rich Al Mounira Children	Sickle Cell Disease	Rifaximin / matching placebo (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients with Sickle Cell Disease	CRO: IQVIA				Hospital, Cairo University /NA 2- MASRI CRC, Faculty of Medicine, Ain Shams University /NA 3- Pediatric Hematology Department, Faculty of Medicine, Zagazig University Hospital /NA 4-CRC, Cairo University /NA 5- CRC, Faculty of Medicine, Alexandria University /NA			
--	--	--	--	------------	--	--	--	--	--	--	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



60.	22/01/2023	AT/03A-017	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19	Sponsor: Atea Pharmaceuticals CRO: Avicemer	III	Approval 15/10/2023	Withdrawn 07/04/2024	1- National Hepatology and Tropical Medicine Research Institute (NHTMRI) /NA	COVID-19	Bemnifosbuvir/ matching Placebo (Pharmaceutical)	NA
61.	13/02/2023	ENRICH-AF	Edoxaban for Intracranial Haemorrhage Survivors with Atrial Fibrillation	Sponsor: Hamilton Health Science	IV	Approval 10/05/2023	Active (31/10/2024)	1- MASRI CRC, Faculty of Medicine, Ain Shams University (10/09/2020).	Atrial Fibrillation in patients with previous Intracranial Haemorrhage	Edoxaban (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			(ENRICH- AF)	CRO: Clinmax				2- Neurology Department, Faculty of Medicine, Zagazig University Hospital (21/05/2021). 3-Neurology Department, Fayoum General Hospital (15/09/2020). 4- Neurology Department, Faculty of Medicine, Tanta University Hospital, (27/10/2020)			
--	--	--	-----------------	-----------------	--	--	--	---	--	--	--

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



								5-Neurology Department, Faculty of Medicine, Mansoura University Hospital (19/10/2020). 6- CRC, Faculty of Medicine, Alexandria University, (09/11/2020) 7- Neurology Department, Faculty of Medicine Assiut University Hospital (30/04/2022).			
62.	13/02/2023	GBT440-038	An Open-Label	Sponsor: GBT	III	Approval 30/03/2023	IMP Dosing Pause	1-CRC, Faculty of Medicine,	Sickle Cell Disease	Voxelotor	Click Here

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Extension Study of Voxelotor Administered Orally to Paediatric Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials	(Subsidiary of Pfizer)			02/05/2024 Terminated (by the Sponsor) 26/09/2024	Alexandria University (29/01/2024). 2- Pediatrics Hematology Department, Faculty of Medicine, Zagazig University Hospital (10/12/2023). 3-Pediatrics Hematology Department, Abu El Rich Al Mounira Children Hospital, Cairo University (13/03/2024) 4- MASRI CRC, Faculty of		(Pharmaceutical)	
--	--	--	---	------------------------	--	--	--	---	--	------------------	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



								Medicine, Ain Shams University (21/02/2024).			
63.	01/03/2023	GN41851 FENHANCE	A Phase III Multicentre, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with	Sponsor: Roche	III	Approval 26/04/2023	Withdrawn 11/01/2024	1-CRC, Faculty of Medicine, Alexandria University/NA	Relapsing multiple sclerosis	Fenebrutinib/ Teriflunomide/ matching placebo (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Relapsing Multiple Sclerosis. (FENHANCE)								
64.	06/03/2023	1305-0023 (FIBRONEER –ILD)	A Double Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over At Least 52 Weeks in Patients with Progressive Fibrosing Interstitial	Sponsor: Boehringer Ingelheim CRO: IQVIA	III	Approval 01/06/2023	Withdrawn 17/01/2024	1- MASRI CRC, Faculty of Medicine Ain Shams University /NA 2-CRC, Faculty of Medicine, Alexandria University /NA 3- CRC Air Force Specialized Hospital /NA 4- CRC, Faculty of Medicine, Cairo University /NA	Progressive Fibrosing Interstitial Lung Diseases (PF- ILDs)	BI 1015550 / matching placebo (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Lung Diseases (PF- ILDs) ((FIBRONEER -ILD)								
65.	06/03/2023	1305- 0014 (FIBRON EER – IPF)	A Double Blind, Randomized, Placebo- Controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over At Least 52 Weeks in Patients with Idiopathic Pulmonary Fibrosis (IPF)	Sponsor: Boehring er Ingelheim CRO: IQVIA	III	Approval 01/06/2023	Withdrawn 08/01/2024	1- MASRI CRC, Faculty of Medicine Ain Shams University /NA 2- CRC, Faculty of Medicine, Alexandria University /NA 3- CRC, Air Force Specialized Hospital /NA 4- CRC, Faculty of Medicine, Cairo University /NA	Idiopathic Pulmonary Fibrosis (IPF)	BI 1015550 / matching placebo (Pharmaceutical)	NA

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			(FIBRONEER – IPF)								
66.	16/03/2023	4202-HEM-201	A Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of FT-4202 in Patients with Thalassemia or Sickle Cell Disease	Sponsor: Forma Therapeutics CRO: MCT	II	Approval 01/06/2023	Completed 24/09/2025	1- Pediatrics Hematology Department, Abu El-Rich Al Mounira Children Hospital, Cairo University (12/07/2024). 2-CRC, Faculty of Medicine, Cairo University (12/07/2024).	Thalassemia or Sickle Cell Disease	Etavopivat (Pharmaceutical)	NA
67.	15/05/2023	EFC16035 (PERSEUS)	A Phase 3, Randomized, Double-Blind, Efficacy and Safety Study Comparing	Sponsor: Sanofi	III	Approval 10/08/2023	Withdrawn 15/04/2024	1- CRC, Faculty of Medicine Alexandria University /NA	Primary Progressive Multiple Sclerosis	Tolebrutinib/ Matching Placebo (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			SAR442168 to Placebo in Participants with Primary Progressive Multiple Sclerosis (PERSEUS)								
68.	14/03/2024	WO43571 HereDERA	A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination with Phesgo Versus Phesgo After	Sponsor: Roche	III	Approval 08/04/2024	Active (28/04/2025)	1- Sohag Oncology Center (19/09/2024) 2- Gustave Roussy International Hospital (19/09/2024) 3- National Cancer Institute - Breast Cancer Treatment &	Previously Untreated Her2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer	Giredestrant (Pharmaceutical)	Click Here

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة

البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg

التليفون: 0237484988

موقع الهيئة: www.edaegypt.gov.eg

			Induction Therapy with Phesgo+ Taxane in Patients with Previously Untreated Her2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer HereDERA)					Research Hospital (08/12/2024)			
69.	22/04/2024	1517-CL-1003	A Phase 3, Open-label, Uncontrolled Study to	Sponsor: Astellas Pharma Global	III	Approval 10/07/2024	Withdrawn 26/09/2024	1- Abu Al Rich Al Mounira Children's	Anemia in Pediatric Patients with Chronic	Roxadustat (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Evaluate the Activity, Safety, Pharmacokinetics and Pharmacodynamics of Roxadustat for the Treatment of Anemia in Pediatric Participants with chronic kidney disease 1517-CL-1003	Development CRO: MCT				Hospital, Cairo University /NA 2- MASRI CRC, Faculty of Medicine, Ain Shams University /NA 3- CRC, Faculty of Medicine, Alexandria University /NA	Kidney Disease		
70.	05/06/2024	M23-698	A Phase 3, Randomized, Placebo-Controlled, Double-Blind	Sponsor: Abbvie	III	Approval 07/08/2024	Withdrawn 09/04/2025	1- MASRI CRC, Faculty of Medicine, Ain Shams University /NA	Moderate to Severe Hidradenitis Suppurativa	Upadacitinib (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy M23-698					2- CRC, Air Force Specialized Hospital /NA 3- CRC, Faculty of Medicine, Alexandria University/NA			
71.	16/12/2024	DAY101-002	A Phase 3, Randomized, International Multicenter	Sponsor: Day One Biopharmaceuticals	III	Approval 19/02/2025	Active (06/05/2026)	1- CRC, Children Cancer Hospital Egypt-57357 (16/10/2025).	Pediatric Low-Grade Glioma Harboring an Activating	Tovorafenib (Pharmaceutical)	Click Here

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy	CRO: MCT					RAF Alteration Requiring First-Line Systemic Therapy		
--	--	--	---	-------------	--	--	--	--	---	--	--

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



72.	29/01/2025	NN7535-7822 FLORAL	An Open-Label, Multi-Centre, Rollover Study to Characterise Long-Term Safety and Efficacy of Etavopivat in Adults, Adolescents and Children Who Have Sickle Cell Disease or Thalassaemia and Have Completed a Treatment Period in an	Sponsor: Forma Therapeutics CRO: IQVIA	III	Approval 10/04/2025	Recruiting (27/08/2025)	1- CRC, Faculty of Medicine, Alexandria University /NA 2- Pediatrics Hematology Department, Zagazig University Hospital /NA 3- CRC, Faculty of Medicine, Cairo University (27/08/2025). 4- MASRI CRC, Faculty of Medicine, Ain Shams University (05/07/2026)	Adults, Adolescents and Children Who Have Sickle Cell Disease or Thalassaemia	Etavopivat (Pharmaceutical)	NA
-----	------------	-----------------------	--	---	-----	------------------------	----------------------------	---	---	-----------------------------	----

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة

البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg

التليفون: 0237484988

موقع الهيئة: www.edaegypt.gov.eg

			Etavopivat Study (FLORAL)					5- Pediatrics Hematology Department, Abu El Rich Al Mounira Children Hospital, Cairo University (27/08/2025)			
73.	16/06/2025	ID-064A301 (OPUS-1)	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of	Sponsor: Idorsia Pharmaceuticals CRO: RAY	III	Approval 10/08/2025	Withdrawn 21/01/2026	1- CRC Air Force Specialized Hospital /NA 2- CRC, Faculty of Medicine, Alexandria University /NA 3- MASRI CRC, Faculty of Medicine, Ain Shams University /NA.	Adult Subjects with Moderate to Severe Systemic Lupus Erythematosus	Cenerimod (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Cenerimod in Adult Subjects with Moderate-to-Severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy (OPUS-1)								
74.	30/07/2025	1397-0014	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy,	Sponsor: Boehringer Ingelheim International GmbH	III	Approval 08/10/2025	Withdrawn 08/02/2026	1- Air Force Specialized Hospital CRC /NA 2- CRC, Faculty of Medicine, Alexandria University /NA	Bronchiectasis	BI 1291583 2.5 mg/matching placebo (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for Up to 76 Weeks in Patients With Bronchiectasis (The AIRTIVITY® Study)	CRO: IQVIA				3- MASRI CRC, Faculty of Medicine, Ain Shams University /NA			
75.	25/08/2025	D6972C00002	A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to	Sponsor: Astra Zeneca CRO: IQVIA	III	Approval 11/11/2025	Withdrawn 03/03/2026	1-CRC, Faculty of Medicine, Alexandria University /NA 2- MASRI CRC, Faculty of Medicine, Ain	Chronic Kidney Disease and High Blood Pressure	Baxdrostat & Dapagliflozin (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants with Chronic Kidney					Shams University /NA 3- National Institute of Urology and Nephrology /NA 4- Urology & Nephrology Center, Mansoura University /NA 5- Urology Department, Specialized Medical Hospital, Mansoura University /NA			
--	--	--	---	--	--	--	--	--	--	--	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Disease and High Blood Pressure (Bax-Duo PACIFIC)								
76.	08/09/2025	1378-0041	A Phase III Double-Blind, Randomised, Parallel-Group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrost (BI 690517) and Empagliflozin	Sponsor: Boehringer International GmbH CRO: IQVIA	III	Approval 30/11/2025	Withdrawn 10/12/2025	1- CRC, Faculty of Medicine, Alexandria University /NA 2- MASRI CRC, Faculty of Medicine Ain Shams University /NA 3- CRC, Faculty of Medicine, Cairo University /NA	Type 2 Diabetes, Hypertension and Established Cardiovascular Disease	Vicadrost (BI 690517) and Empagliflozin (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Compared With Placebo and Empagliflozin in Participants with Type 2 Diabetes, Hypertension and Established Cardiovascular Disease								
77.	18/09/2025	AT-01B-008	An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-	Sponsor: Atea Pharmaceuticals	III	Approval 15/12/2025	Active (24/06/2026)	1- National Hepatology and Tropical Medicine Institute (NHTMRI) (05/06/2026)	Chronic Hepatitis C Virus (HCV)	Bemnifosbuvir-Ruzasvir and Sofosbuvir-Velpatasvir (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study	CRO: AVICEM ER				2- CRC Air Force Specialized Hospital /NA			
78.	18/09/2025	GLOBOT RK	Phase 2 Study of Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age	Sponsor: St. Jude Children's Research Hospital	II	Approval 18/12/2025	-----	1- CRC, Children Cancer Hospital Egypt 57357 /NA	NTRK1/2/3 or ROS-1-Fused CNS Tumors	Entrectinib (Pharmaceutical)	NA

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			with NTRK1/2/3 or ROS-1-Fused CNS Tumors (GLOBOTRK)	CRO: MCT							
79.	24/07/2022	MD-004	Open labelled non randomized self-controlled study to evaluate the safety and performance of Ezvent in hospitalized mechanically ventilated patients	Sponsor: Ezz Medical Industries CRO: Dataclin	III (pivotal)	Approval 28/08/2022	Suspended 01/01/2024 Resumed 13/01/2024 Completed 03/06/2025	1-Critical Care Unit, Kasr Al Aini Hospital, Cairo University (25/10/2022)	Hospitalized mechanically ventilated patients	Ezvent (Medical device)	NA

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة

البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg

التليفون: 0237484988

موقع الهيئة: www.edaegypt.gov.eg



80.	15/05/2022	COAV10 1B12301	A randomized sham controlled double –blind study to evaluate the efficacy and safety of intrathecal (IT) QAV101 in patients with later onset type 2 spinal muscular atrophy (SMA) who are ≥ 2 to <18 years of age, treatment naïve sitting	Sponsor: Novartis CRO: MCT	III	Approval 02/08/2022	Terminated (by the Sponsor) 18/12/2023	1-Department of Neurology, Ain Shams University Specialized Hospital (11/05/2023)	type 2 spinal muscular atrophy (SMA)	QAV101 (Zolgensma) (Onasemnogene abeparvovec)	NA
-----	------------	-------------------	---	-----------------------------------	-----	------------------------	--	--	--------------------------------------	---	----

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			and never ambulatory								
81.	06/06/2023	Urso-003	Multi-Center, randomized, control, phase IV trial to compare the efficacy & safety of Ursoplus® capsules (UDCA 250mg & Silymarin 140mg) versus UDCA alone versus Placebo among Compensated Chronic Liver	Sponsor: Minaphar m CRO: Dataclin	IV	Approval 18/09/2023	Suspended (Recruitment suspension) 26/11/2024	1-CRC, Air Force Specialized Hospital (01/03/2022) 2-National Hepatology and Tropical Research Institute (NHTMRI) /NA	Compensated Chronic Liver Disease Patients	Ursoplus® capsules/ Ursofalk® capsules (Innovative)	NA

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



			Disease Patients								
82.	06/06/2023	Cipro-001	Single center, Open Label, controlled Study to assess the safety & efficacy of Oral Ciprofloxacin ® Tablets (Ciprofolxacin / Metronidazole) versus currently used Ciprofloxacin Tablets & Metronidazole tablets in pelvi-	Sponsor: Minapharm, CRO: Nagy Research	IV	Refusal 12/09/2023	Suspended 12/09/2023	1- General Surgery Department, Menoufia University Hospital. (10/10/2021)	Pelvi-abdominal infections and following IV antibiotics in post-operative period, for pelvi-abdominal surgeries or acute conditions	Ciprofloxacin ® Tablets (Ciprofolxacin/ Metronidazole) (Innovative)	NA

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجيزة - الجيزة

البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg

التليفون: 0237484988

موقع الهيئة: www.edaegypt.gov.eg

			abdominal infections and following IV antibiotics in post-operative period, for pelvi-abdominal surgeries or acute conditions								
--	--	--	---	--	--	--	--	--	--	--	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



83.	31/07/2023	GRC\AD GE\EG\3 8\III	A Randomized, Open-label, Active- Controlled Clinical Trial to Investigate the Efficacy and Sa fety of Ondansetron compared to Metoclopramid e in the management of Nausea and Vomiting in Adult Patients with Acute Gastroenteritis(GRC\ADGE\EG\38\III)	Sponsor: Adwia CRO: Genuine research center (GRC)	IV	Refusal 28/11/2023	NA	1. Faculty of Medicine, Beni- Suef University Hospital/ NA 2. Faculty of Medicine, Fayoum University Hospital/ NA 3. Faculty of Medicine, Benha University Hospital/ NA	Nausea and Vomiting in Adult Patients with Acute Gastroenteritis	Ondansetron (Innovative)	NA
-----	------------	----------------------------	---	---	----	-----------------------	----	---	--	---------------------------------	----

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



84.	24/10/2023	GRC/NE-CV/EG/39/IV	A prospective, Multicentre, Open-label, Single-arm Interventional Study of Bisoprolol (Nerkardou) (Between Low Dose and High Dose) 5 and 10 mg ODF Treatment in Egyptian Patients with Essential Hypertension	Sponso Nerhadou Internatio-nal CRO: Genuine research center	IV	Approval 10/03/2024	Terminated (by the sponsor) 13/05/2025	1- Department of General Internal Medicine, Beni-Suef University Hospital (22/10/2024) 2- Department of Cardiology and Vascular Medicine, Fayoum University Hospital (07/08/2024)	Essential Hypertension	Nerkardou (Bisoprolol) Oral dispersible film (Innovative)	Click here
-----	------------	--------------------	---	--	----	---------------------	--	--	------------------------	--	----------------------------

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



85.	13/08/2025	START24 042025	Adhesion and Safety of Rotigexole Compared to Neupro®: A Non- Inferiority Open-Labelled Crossover Randomized Controlled Trial.	Sponsor: Eva Pharma CRO: MARC	IV	Approval 13/11/2025	Recruiting 09/02/2026	1- MARC CRC (09/02/2026) 2- Department of Neurology, Ain Shams Specialized Hospital (26/02/2026) 3- Department of Neurology, Al Manial Specialized Hospital, Cairo University (29/03/2026)	Parkinson's Disease	Rotigotine 8 mg/24h Transdermal Patch (Innovative)	Click Here
-----	------------	-------------------	---	---	----	------------------------	--------------------------	--	------------------------	--	--------------------------------

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



86.	25/08/2024	NW- Roselle- 572023	Efficacy and safety of Roselle in phase III, randomized, double -blind, double dummy, active controlled clinical trial	Sponsor: Natural wellness CRO: Clinmax	III	Refusal 15/01/2025	NA	1- Cardiology Department, Faculty of Medicine, Alexandria University Hospitals/NA 2- Cardiology Department Faculty of Medicine, Mansoura University Hospitals/NA 3- Fayoum General Hospital/NA	Hypertension	Hibiscus sabdariffa, Olea europaea L (Herbal)	NA
-----	------------	---------------------------	---	--	-----	-----------------------	----	---	--------------	--	----

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg



87.	02/09/2024	NW_Low Glu_1805 2023	A Phase III, Randomized, Double-Blind, Double- Dummy, Active- Controlled Clinical Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients with Type II Diabetes Mellitus	Sponsor: Natural wellness CRO: Dataclin	III	Refusal 22/05/2025	NA	1- Internal Medicine Department, Faculty of Medicine, Alexandria University/NA 2- Internal Medicine Department, Faculty of Medicine, Alazahar University/NA 3- Internal Medicine Department, Imbaba General Hospital/NA	Type II Diabetes Mellitus	Mas Cotek powdered Extract 300 mg Cinnamomum cassia, Black seed powdered extract 250 mg) (Herbal)	NA
-----	------------	----------------------------	---	---	-----	-----------------------	----	--	---------------------------------	--	----

*** Study Status:**

- Pending activation: Not yet recruiting: The study has not started recruiting participants.

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة

البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg

التليفون: 0237484988

موقع الهيئة: www.edaegypt.gov.eg

- **Recruiting:** The study is currently recruiting participants.
- **Active:** Not recruiting, the study is ongoing, and participants are receiving an intervention or being examined or followed up, but potential participants are not currently being recruited or enrolled.
- **Suspended:** The study has stopped early but may start again.
- **Terminated:** The study has stopped early and will not start again. But the participants may be still examined or followed up.
- **Completed:** The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

العنوان: 51 شارع وزارة الزراعة، العجوزة - الجيزة
البريد الإلكتروني: المكتب الفني / bio.tech@edaegypt.gov.eg ، المكتب الإداري / bio.admin@edaegypt.gov.eg
التليفون: 0237484988
موقع الهيئة: www.edaegypt.gov.eg